Evidence map›Paper›PMID 34138902›Full record

ArticlePloS one2021

Lack of APOL1 in proximal tubules of normal human kidneys and proteinuric APOL1 transgenic mouse kidneys.

Natalya A Blessing, Zhenzhen Wu, Sethu M Madhavan, Jonathan W Choy, Michelle Chen, Myung K Shin, Maarten Hoek, John R Sedor, John F O'Toole, Leslie A Bruggeman

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Clinical journal of the American Society of Nephrology : CJASN · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalya A BlessingRammelkamp Center for Education and Research, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Zhenzhen WuDepartment of Inflammation & Immunity, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Sethu M MadhavanDepartment of Medicine, Ohio State University, Columbus, OH, United States of America.
Jonathan W ChoyMerck & Company, Inc., Kenilworth, NJ, United States of America.
Michelle ChenMerck & Company, Inc., Kenilworth, NJ, United States of America.
Myung K ShinMerck & Company, Inc., Kenilworth, NJ, United States of America.
Maarten HoekMaze Therapeutics, South San Francisco, CA, United States of America.ORCID 0000-0002-5237-1626
John R SedorDepartment of Inflammation & Immunity, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
John F O'TooleDepartment of Inflammation & Immunity, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.
Leslie A BruggemanDepartment of Inflammation & Immunity, Cleveland Clinic, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America.ORCID 0000-0001-5874-705X

Funding

CWRU NEPHROLOGY TRAINING PROGRAMT32DK007470 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI SEDOR, JOHN R. · 1986 to 2019
$2.9M
Mechanisms of APOL1-mediated kidney diseaseR01DK108329 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2015 to 2019
$2.0M
Kidney disease mechanisms associated with human genetic variationR01DK097836 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2014 to 2017
$2.0M
Cell junction proteins in podocyte injury repairR01DK095832 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI BRUGGEMAN, LESLIE A, SIMSKE, JEFFREY · 2012 to 2015
$1.3M
Apolipoprotein L1 Interaction with SNARE Proteins in the Pathogenesis of Chronic Kidney DiseaseK08DK123411 · NIDDK · OHIO STATE UNIVERSITY · PI MADHAVAN, SETHU MADHAVAN · 2020 to 2024
$805k
NIDDK NIH HHS K08 DK123411NIDDK NIH HHS R01 DK095832NIDDK NIH HHS R01 DK097836NIDDK NIH HHS R01 DK108329NIDDK NIH HHS T32 DK007470
6 · The paper itself

Abstract

The mechanism of pathogenesis associated with APOL1 polymorphisms and risk for non-diabetic chronic kidney disease (CKD) is not fully understood. Prior studies have minimized a causal role for the circulating APOL1 protein, thus efforts to understand kidney pathogenesis have focused on APOL1 expressed in renal cells. Of the kidney cells reported to express APOL1, the proximal tubule expression patterns are inconsistent in published reports, and whether APOL1 is synthesized by the proximal tubule or possibly APOL1 protein in the blood is filtered and reabsorbed by the proximal tubule remains unclear. Using both protein and mRNA in situ methods, the kidney expression pattern of APOL1 was examined in normal human and APOL1 bacterial artificial chromosome transgenic mice with and without proteinuria. APOL1 protein and mRNA was detected in podocytes and endothelial cells, but not in tubular epithelia. In the setting of proteinuria, plasma APOL1 protein did not appear to be filtered or reabsorbed by the proximal tubule. A side-by-side examination of commercial antibodies used in prior studies suggest the original reports of APOL1 in proximal tubules likely reflects antibody non-specificity. As such, APOL1 expression in podocytes and endothelia should remain the focus for mechanistic studies in the APOL1-mediated kidney diseases.

Indexed as

AllelesAnimalsApolipoprotein L1Endothelial CellsHumansKidneyKidney Tubules, ProximalLiverMiceMice, TransgenicPodocytesProteinuriaApolipoprotein L1

Identifiers

PMID34138902
PMCPMC8211208

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.